405 related articles for article (PubMed ID: 29882591)
1. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review.
Tomaselli Muensterman E; Tisdale JE
Pharmacotherapy; 2018 Aug; 38(8):813-821. PubMed ID: 29882591
[TBL] [Abstract][Full Text] [Related]
2. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
3. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Mourad NA; Trujillo TN; Overholser BR; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):479-87. PubMed ID: 23716032
[TBL] [Abstract][Full Text] [Related]
6. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for QTc-prolongation: systematic review of the evidence.
Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
Int J Clin Pharm; 2017 Feb; 39(1):16-25. PubMed ID: 28012118
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Overholser BR; Mourad NA; Trujillo TN; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):381-90. PubMed ID: 24803473
[TBL] [Abstract][Full Text] [Related]
9. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
[TBL] [Abstract][Full Text] [Related]
10. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
11. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
13. Personalized, intuitive & visual QT-prolongation monitoring using patient-specific QTc threshold with pseudo-coloring and explainable AI.
Alahmadi A; Davies A; Vigo M; Jay C
J Electrocardiol; 2023; 81():218-223. PubMed ID: 37837739
[TBL] [Abstract][Full Text] [Related]
14. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.
Tisdale JE
Can Pharm J (Ott); 2016 May; 149(3):139-52. PubMed ID: 27212965
[TBL] [Abstract][Full Text] [Related]
17. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
[TBL] [Abstract][Full Text] [Related]
18. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
19. Navigating the Minefield of QTc Interval-Prolonging Therapy in Nursing Facility Residents.
Zarowitz BJ; Tisdale JE
J Am Geriatr Soc; 2019 Jul; 67(7):1508-1515. PubMed ID: 30747995
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.
Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK
Ther Adv Psychopharmacol; 2014 Jun; 4(3):130-8. PubMed ID: 25057346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
